This Phase 2 clinical trial investigates dimethyl fumarate (DMF), an established multiple sclerosis drug with potent Nrf2-activating properties, as a potential disease-modifying treatment for Alzheimer's disease. The trial represents a drug repurposing approach, taking advantage of the well-characterized safety profile of DMF (marketed as Tecfidera for multiple sclerosis) to target neuroprotective pathways via Nrf2 transcription factor activation in AD[@nct].
The study addresses a critical gap in AD therapeutics by targeting the oxidative stress and neuroinflammation components of the disease that are not addressed by current amyloid-targeting approaches. Oxidative stress is one of the earliest detectable pathological features in AD, and the Nrf2 pathway is the cell's primary defense mechanism against oxidative damage[@nrf22023].
Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans and 55 million people worldwide. The disease is characterized by progressive cognitive decline, with memory loss being the most prominent early symptom. Despite extensive research, no cure exists, and current treatments provide only modest symptomatic benefit. This has driven interest in drug repurposing—identifying existing drugs with mechanisms that may address AD pathology.
Dimethyl fumarate represents a compelling candidate for repurposing due to its established safety profile in multiple sclerosis, its ability to activate the Nrf2 pathway (which is dysregulated in AD), and its anti-inflammatory properties. The Medical University of Lodz in Poland is conducting this Phase 2 trial to evaluate whether DMF can slow cognitive decline in patients with mild-to-moderate AD.
Oxidative stress is recognized as a central pathological feature of Alzheimer's disease, with evidence of oxidative damage present even in early disease stages. The brain is particularly vulnerable to oxidative damage due to:
In AD, multiple sources of oxidative stress converge:
Mitochondrial Dysfunction:
Metal Homeostasis:
Inflammation-Associated ROS:
Advanced Glycation End Products (AGEs):
Multiple biomarkers demonstrate oxidative stress in AD:
| Biomarker | Change in AD | Source |
|---|---|---|
| 8-OHdG (DNA oxidation) | Increased | Brain tissue, CSF, urine |
| 4-HNE (lipid peroxidation) | Increased | Brain tissue, plasma |
| 8-iso-PGF2α (lipid peroxidation) | Increased | Plasma, urine |
| Protein carbonyls | Increased | Brain tissue, plasma |
| GSH/GSSG ratio | Decreased | Brain tissue, CSF |
| SOD activity | Variable | Brain tissue |
This oxidative damage correlates with cognitive decline and disease severity, making antioxidant pathways attractive therapeutic targets.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of cellular defense against oxidative stress. This transcription factor controls the expression of over 200 genes involved in antioxidant responses, xenobiotic metabolism, and cellular protection.
Nrf2 Structure and Function:
Nrf2 is a basic leucine zipper transcription factor encoded by the NFE2L2 gene. It contains seven highly conserved domains (Neh1-7), each with distinct functions:
Regulation by Keap1:
Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and proteasomal degradation. Keap1 acts as a molecular sensor for oxidative stress, containing cysteine residues that are modified by electrophiles.
Activation Mechanism:
Nrf2 regulates a comprehensive network of protective genes:
Phase 2 Detoxification Enzymes:
Antioxidant Proteins:
Other Protective Proteins:
Multiple mechanisms contribute to Nrf2 impairment in AD:
Transcriptional Dysregulation:
Keap1 Overactivation:
Impaired Clearance:
Therapeutic Implication:
The "Nrf2 insufficiency" in AD creates a rationale for pharmacological Nrf2 activation. By enhancing Nrf2 activity, it may be possible to restore cellular antioxidant capacity and slow disease progression.
Dimethyl fumarate (DMF) exerts its neuroprotective effects primarily through Nrf2 pathway activation:
The resulting gene expression changes include:
| Gene | Function | Benefit in AD |
|---|---|---|
| NQO1 | Coenzyme Q10 regeneration | Mitochondrial protection |
| HO-1 | Heme degradation, anti-inflammatory | Neuroprotection |
| GCLM | Glutathione synthesis | Antioxidant capacity |
| SOD2 | Superoxide dismutase | Mitochondrial ROS scavenging |
| PRDX1 | Peroxide reduction | Oxidative stress reduction |
| NQO1 | Coenzyme Q10 regeneration | Energy metabolism |
Beyond direct antioxidant effects, Nrf2 activation suppresses neuroinflammation:
Preclinical evidence suggests DMF may affect amyloid pathology:
Nrf2 activation protects mitochondria through:
Dimethyl fumarate (Tecfidera) received FDA approval for relapsing-remitting multiple sclerosis (RRMS) in 2013, providing extensive clinical experience:
Efficacy:
Safety Profile:
Pharmacology:
Alzheimer's disease shares pathological features with multiple sclerosis that DMF may address:
The Nrf2-activating properties of DMF are particularly relevant because:
This creates a strong rationale for testing DMF in AD.
This is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial:
The dosing follows the approved MS regimen with adaptation:
Dimethyl Fumarate Arm:
Placebo Arm:
The titration period reduces flushing and GI side effects seen with rapid dose escalation.
Participants may be stratified by:
This ensures balanced distribution of prognostic factors between arms.
Change in ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale)
Safety and Tolerability
Cerebrospinal Fluid Biomarkers
Brain MRI Volumetry
Functional Assessment
Nrf2 Pathway Biomarkers
DMF has been used in over 500,000 MS patients worldwide, providing extensive safety data:
Common Adverse Events:
Rare Serious Adverse Events:
Long-term Safety:
This established safety profile allows confident testing in AD.
Multiple studies have evaluated DMF in AD models:
APP/PS1 Transgenic Mice:
3xTg-AD Mice:
In Vitro Studies:
Biomarker studies in MS patients demonstrate Nrf2 pathway activation:
This human evidence supports the mechanism being tested in AD.
The MS dose (240 mg twice daily) was selected for:
For AD, questions remain:
The current trial uses the approved MS dose, with biomarker measurements to assess target engagement.
Optimal benefit may be achieved in earlier disease stages:
The trial includes mild-to-moderate AD (MMSE 18-26), which may limit observed effect size.
DMF may be combined with:
This combination rationale may be explored in future trials.
Validating Nrf2 activation in AD brain is challenging:
The trial includes peripheral biomarker assessments as proxies for CNS effects.
As of 2026, this trial is:
Results are expected to inform:
If the trial demonstrates:
This would support:
Negative results would:
This Phase 2 trial represents an important test of the Nrf2 activation hypothesis in Alzheimer's disease. By repurposing dimethyl fumarate—a drug with established safety in MS—researchers can efficiently evaluate whether enhancing antioxidant and anti-inflammatory pathways provides cognitive benefit in AD.
The 48-week design allows detection of clinically meaningful cognitive effects while maintaining reasonable trial duration. The inclusion of biomarker endpoints provides insights into mechanism engagement, enabling interpretation of positive or negative results.
Success would validate Nrf2 as a therapeutic target in AD and potentially provide a new disease-modifying treatment approach. Even if results are negative, the trial provides valuable data about antioxidant strategies in neurodegeneration.
| Parameter | Value |
|---|---|
| NCT Number | NCT06850597 |
| Phase | Phase 2 |
| Status | Active, recruiting |
| Sponsor | Medical University of Lodz (Poland) |
| Enrollment | 30 participants |
| Intervention | Dimethyl fumarate (oral) |
| Comparator | Placebo |
| Duration | 48 weeks |
| Location | Medical University of Lodz, Poland |
| Design | Randomized, double-blind, placebo-controlled |
The Nrf2 (Nuclear factor erythroid 2-related factor 2) transcription factor is the master regulator of cellular antioxidant response. Under normal conditions, Nrf2 is bound to Keap1 (Kelch-like ECH-associated protein 1) in the cytoplasm, which keeps it inactive and promotes its degradation. When cells encounter oxidative stress, Nrf2 is released from Keap1, translocates to the nucleus, and binds to the Antioxidant Response Element (ARE) in DNA, triggering transcription of a battery of protective genes[@cuadrado2022].
Key Nrf2 target genes include:
The Nrf2 pathway is dysfunctional in Alzheimer's disease at multiple levels:
Animal studies demonstrate that Nrf2 deficiency accelerates Alzheimer's-like pathology, while Nrf2 activation is protective[@itoh2015]. This makes the Nrf2 pathway an attractive therapeutic target.
Human post-mortem studies provide strong evidence for Nrf2 pathway dysfunction in AD[@cruz2023]:
Dimethyl fumarate exerts its neuroprotective effects primarily through Nrf2 pathway activation[@pomyt2023]:
DMF → Covalent modification of Keap1 cysteine residues → Nrf2 release → Nuclear translocation → ARE binding → Antioxidant gene expression
Key steps in the mechanism:
Keap1 Modification: DMF (or its metabolite monomethyl fumarate) covalently modifies cysteine residues (C151, C273, C288) on Keap1
Nrf2 Release: This modification changes Keap1's conformation, releasing Nrf2 from sequestration
Nuclear Translocation: Free Nrf2 translocates to the nucleus
ARE Binding: Nrf2 forms heterodimers with small Maf proteins and binds to Antioxidant Response Elements
Gene Expression: Upregulation of ~200 target genes involved in antioxidant defense, detoxification, and cellular protection
DMF undergoes rapid metabolism to monomethyl fumarate (MMF), the active metabolite, which is responsible for Nrf2 activation[@lin2024]:
The Nrf2 pathway addresses multiple AD pathological features:
AD brains exhibit some of the highest levels of oxidative damage in any neurological condition:
Nrf2 activation directly counteracts these processes through upregulation of antioxidant enzymes[@neuroprotection2024].
Nrf2 activation has profound anti-inflammatory effects:
This is particularly important because chronic neuroinflammation drives disease progression in AD[@liu2023].
Preclinical evidence suggests DMF may affect amyloid pathology:
Nrf2 activation may protect against tau pathology:
Nrf2 target genes protect mitochondrial function:
Beyond Nrf2, DMF has additional mechanisms:
| Arm | Intervention | Dose | Duration |
|---|---|---|---|
| Active | Dimethyl fumarate | Titration to 240 mg BID | 48 weeks |
| Placebo | Matching placebo | N/A | 48 weeks |
Titration Schedule (typical for DMF):
| Endpoint | Description |
|---|---|
| CSF Biomarkers | Aβ42, total tau, p-tau181 |
| Brain MRI | Hippocampal volume, cortical thickness |
| ADCS-ADL | Alzheimer's Disease Cooperative Study - Activities of Daily Living |
| Nrf2 Pathway Biomarkers | HO-1, NQO1 expression (PBMCs) |
| Oxidative Stress Markers | 8-OHdG, 4-HNE in CSF |
| Neuroinflammation Markers | IL-1β, IL-6, TNF-α in CSF |
Dimethyl fumarate (Tecfidera) has been FDA-approved for relapsing-remitting multiple sclerosis since 2013, with extensive clinical experience:
Common DMF side effects (usually transient):
These side effects are typically manageable and tend to improve with continued treatment.
Alzheimer's disease brains show specific features that make DMF an attractive candidate:
| AD Pathology | Nrf2 Pathway Effect |
|---|---|
| Chronic oxidative stress | Direct antioxidant enzyme upregulation |
| Neuroinflammation | Suppress pro-inflammatory cytokines |
| Mitochondrial dysfunction | Protect electron transport chain |
| Synaptic loss | Preserve synaptic protein expression |
| Amyloid toxicity | Reduce Aβ-induced oxidative damage |
Multiple preclinical studies support DMF's potential in AD[@chen2023]:
DMF is one of several Nrf2-activating approaches being explored in AD[@yang2024]:
| Compound | Mechanism | Development Stage |
|---|---|---|
| Dimethyl fumarate | Keap1 modification | Phase 2 |
| Bardoxolone methyl | Nrf2 activation via Keap1 | Phase 2 |
| Sulforaphane | Nrf2 activation via Michael addition | Phase 1 |
| CDDO-Me | Nrf2 activation | Preclinical |
This trial represents a critical step in validating Nrf2 activation as a therapeutic strategy in AD:
| Approach | Target | Current Status | Limitation |
|---|---|---|---|
| Anti-amyloid antibodies | Amyloid plaques | Approved (lecanemab, donanemab) | Limited efficacy, brain edema risk |
| Cholinesterase inhibitors | Symptoms | Generic available | Symptomatic only |
| NMDAR antagonist | Symptoms | Generic available | Symptomatic only |
| Nrf2 activators (DMF) | Oxidative stress/neuroinflammation | Phase 2 | Unproven in AD |
If successful, this trial would:
NCT06850597 — Phase 2 Study of Dimethyl Fumarate in Alzheimer's Disease
Kikuchi et al., Nrf2 activation and neuroprotection in Alzheimer's disease (2023)
Gold et al., Dimethyl fumarate in multiple sclerosis - clinical efficacy (2023)
Zhang et al., Nrf2-mediated neuroprotection in neurodegenerative models (2024)
Chen et al., Dimethyl fumarate ameliorates cognitive deficit in APP/PS1 mice (2023)
Itoh et al., Nrf2 deficiency accelerates Alzheimer's-like pathology (2015)
Cuadrado et al., Nrf2-ARE pathway in neurological diseases (2022)
Davidi et al., Nrf2 activation as therapeutic strategy for AD (2024)
Pomytkin et al., Dimethyl fumarate and Nrf2: molecular mechanisms (2023)
Joh et al., Nrf2 and neurodegeneration: cellular interplay (2024)
Şahin et al., Keap1-Nrf2-ARE pathway in Alzheimer's disease (2024)
Fischer et al., Nrf2-targeted therapies in neurodegeneration (2022)
Wang et al., Dimethyl fumarate effects on neuroinflammation in AD models (2024)
Liu et al., Nrf2 regulates neuroinflammation in Alzheimer's disease (2023)
Singh et al., Oxidative stress in Alzheimer's disease: therapeutic targets (2023)
Petersen et al., Nrf2 activators in Alzheimer's disease prevention (2023)
Lin et al., DMF metabolites and Nrf2 activation in the brain (2024)